Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 6, 2010, Pages 869-874

  Park, Eun Kee ^a   Thomas, Paul S ^b   Creaney, Jenette ^c   Johnson, Anthony R ^d   Robinson, Bruce W ^c   Yates, Deborah H ^e  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d LIVERPOOL HOSPITAL   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

Author keywords

Asbestos; Biomarker; Confounding factors; Pulmonary Function; Soluble mesothelin related protein

Indexed keywords

ASBESTOS; CARBON MONOXIDE; CREATININE; GLUCOSE; MESOTHELIN;

ADULT; AGED; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL;

AGED; ASBESTOS; BLOOD GLUCOSE; CARCINOGENS; CREATININE; DEMOGRAPHY; ENVIRONMENTAL EXPOSURE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77953194522     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.165     Document Type: Article

References (30)

1. Howel D, Gibbs A. Mineral fibre analysis and routes of exposure to asbestos in the development of mesothelioma in an English region. Occup Environ Med 1999;56:51-58
2. Agudo A, Gonzalez CA, Bleda MJ. Occupation and risk of malignant pleural mesothelioma: a case-control study in Spain. Am J Ind Med 2000;37:159-168 (Pubitemid 30036726)
3. Zellos L, Christiani DC. Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac Surg Clin 2004;14: 479-487
4. Scherpereel A, Lee YC. Biomarkers for mesothelioma. Curr Opin Pulm Med 2007;13:339-343
5. Bianchi C, Giarelli L, Grandi G, Brollo A, Ramani L, Zuch C. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prevent 1997;6:162-166
6. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005;92:587-593
7. Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest 1998;113(Suppl 1): 66S-73S.
8. Martino D, Pass HI. Integration of multimodality approaches in the management of malignant pleural mesothelioma. Clin Lung Cancer 2004;5:290-298
9. Hyland RA, Ware S, Johnson AR, Yates DH. Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia. Scand J Work Environ Health 2007;33: 286-292
10. O'Lone EL, Park EK, Sandrini A Fogarty GB, Yates DH. Early detection of malignant pleural mesothelioma through measurement of soluble mesothelin-related protein and emission tomography. Med J Aust 2009;190:158-159
11. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, Klerk ND, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-1616
12. Scherpereel A, Grigorlu B, Conti M, Gey T, Gregoire M, Copin M-C, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;173:1155-1160
13. Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, et al. Mesomark™: a potential test for malignant pleural mesothelioma. Clin Chem 2007;53:666-672
14. Creaney J, van Bruggen I, Yeoman D, Hof M, Segal A, Musk AW, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 2007;132:1239-1246 (Pubitemid 47620999)
15. De Serio F, Fontana A, Loizzi M, Capotorto G, Maggiolini P, Mera E, et al. Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results. Clin Chem Lab Med 2007;45: 634-638
16. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007;13:2928-2935
17. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesotheliom, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996;93:136-140
18. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellstrom KE, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 1999;96: 11531-11536
19. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-1428
20. Hollevoet K, Bernard D, De Geeter F, Walgraeve N, Van den Eeckhaut A, Vanholder R, et al. Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum. Clin Chem 2009;55:1431-1433
21. Park E-K, Sandrini A, Yates DH, Creaney J, Robinson BW, Thomas PS, et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med 2008;178:832-837
22. American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 2004;170:691-715.
23. National Heart Foundation of Australia. Guide to management of hypertension 2008. Updated August 2009. Web version. http://www.heartfoundation. org.au/ professional-information / Clinical-Practice / Hypertension.
24. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995;152:1107-1136
25. American Thoracic Society. Single breath carbon monoxide diffusing capacity (transfer factor), recommendations for a standard technique, 1995 update. Am J Respir Crit Care Med 1995; 152:2185-2198
26. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault J-C. Standardization of the measurement of transfer factor (diffusing capacity), report working party standardization of lung function tests, European Community for steel and coal: official statement of the European Respiratory Society. Eur Respir J 1993; 6(Suppl 16):41-53.
27. US FDA. Fujirebio Mesomark™ Assay. Humanitarian Device Exemption Number H060004, Document number 07M-0038. Approval date Jan 24, 2007.
28. Luo L, Shi H-Z, Liang Q-L, Jiang J, Qin S-M, Deng J-M. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. Respir Med 2010; 104:149-156
29. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol 2004;35:697-710.
30. Hyland RA, Yates DH, Benke G, Sim M, Johnson AR. Occupational exposure to asbestos in NSW, Australia 1970-1989: development of an asbestos task exposure matrix. Occup Environ Med 2010;67:201-206